Omnix Medical secures $25 million in Series C funding to advance its antimicrobial peptide, OMN6, in the fight against antibiotic-resistant bacterial infections.

Target Information

Omnix Medical, based in Jerusalem, is a biotechnology company focused on the development of innovative anti-infective drugs. Founded in 2015, Omnix specializes in engineering antimicrobial peptides that aim to combat severe bacterial infections. The company has recently completed a $25 million Series C funding round, co-led by Harel Insurance & Finance and the European Innovation Council (EIC) Fund, with continued support from existing investors.

This new infusion of capital will primarily fund Phase II proof-of-concept studies for its lead compound, OMN6. This latest funding follows an earlier round in November 2020, where the company raised $8.5 million. Overall, Omnix has successfully secured $46 million across five funding rounds, positioning itself strategically in the fight against antibiotic resistance.

Industry Overview

The global biotechnology market is experiencing significant growth, particularly in the anti-infective segment, driven by a rising incidence of antibiotic-resistant infections. Countries inc